Pandemic Treatment Access and Affordability Act of 2021

Summary

Pandemic Treatment Access and Affordability Act of 2021 This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies. With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill. The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access. If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 28 January 2021

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

2. 28 January 2021

   Introduced

   Introduced in House

   Source: IntroReferral

3. 28 January 2021

   Introduced

   Introduced in House

   Source: IntroReferral

4. 2 February 2021

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

5. 22 March 2021

   Referred

   Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 28 January 2021 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 28 January 2021

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 28 January 2021

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 28 January 2021

  Open at official source

Sponsors

• Rep. Schakowsky, Janice D. [D-IL-9] · D · Sponsor
• Rep. Doggett, Lloyd [D-TX-37] · D · Sponsor
• Rosa DeLauro · D · Sponsor
• PETER DEFAZIO · D · Sponsor
• Raúl Grijalva · D · Sponsor
• Rep. Khanna, Ro [D-CA-17] · D · Sponsor
• Rep. Raskin, Jamie [D-MD-8] · D · Sponsor
• Rep. Pingree, Chellie [D-ME-1] · D · Sponsor
• Sen. Welch, Peter [D-VT] · D · Sponsor
• Rep. Pocan, Mark [D-WI-2] · D · Sponsor
• Sanford Bishop · D · Sponsor
• Del. Norton, Eleanor Holmes [D-DC-At Large] · D · Sponsor
• Betty McCollum · D · Sponsor
• Rep. Jayapal, Pramila [D-WA-7] · D · Sponsor
• Rep. Chu, Judy [D-CA-28] · D · Sponsor
• Michael San Nicolas · D · Cosponsor
• Rep. Carson, André [D-IN-7] · D · Cosponsor
• Dwight Evans · D · Cosponsor
• ALCEE HASTINGS · D · Cosponsor
• Rep. DeSaulnier, Mark [D-CA-10] · D · Cosponsor
• Rep. Scanlon, Mary Gay [D-PA-5] · D · Cosponsor
• Rep. Titus, Dina [D-NV-1] · D · Cosponsor
• Al Lawson · D · Cosponsor
• Rep. Cohen, Steve [D-TN-9] · D · Cosponsor
• Jahana Hayes · D · Cosponsor
• DAVID PRICE · D · Cosponsor
• Bennie Thompson · D · Cosponsor
• · hsju00 · Standing
• · hsif00 · Standing
• · hsas00 · Standing
• · hssy00 · Standing

Related records

• related to ← MMAPPP Act of 2020